4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 9,530,000 shares, a decrease of 7.8% from the July 15th total of 10,340,000 shares. Based on an average daily trading volume, of 874,700 shares, the short-interest ratio is currently 10.9 days.

Insider Activity

In related news, CEO David Kirn sold 12,930 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the sale, the chief executive officer now directly owns 1,059,153 shares in the company, valued at $24,466,434.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other 4D Molecular Therapeutics news, insider Scott Bizily sold 1,750 shares of the stock in a transaction dated Tuesday, July 16th. The stock was sold at an average price of $27.11, for a total transaction of $47,442.50. Following the completion of the sale, the insider now directly owns 6,781 shares in the company, valued at approximately $183,832.91. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO David Kirn sold 12,930 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $23.10, for a total value of $298,683.00. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares of the company’s stock, valued at $24,466,434.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 33,847 shares of company stock valued at $777,401. Company insiders own 7.30% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Hedge funds have recently bought and sold shares of the company. Bfsg LLC bought a new position in shares of 4D Molecular Therapeutics during the fourth quarter valued at about $30,000. Allspring Global Investments Holdings LLC lifted its position in shares of 4D Molecular Therapeutics by 702.1% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares in the last quarter. Daiwa Securities Group Inc. boosted its stake in shares of 4D Molecular Therapeutics by 23.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 5,872 shares of the company’s stock worth $119,000 after buying an additional 1,110 shares during the last quarter. Quest Partners LLC grew its holdings in shares of 4D Molecular Therapeutics by 17,409.1% in the second quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after acquiring an additional 5,745 shares in the last quarter. Finally, Entropy Technologies LP purchased a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $239,000. 99.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the company. Chardan Capital reissued a “buy” rating and issued a $38.00 price target on shares of 4D Molecular Therapeutics in a research note on Wednesday, July 17th. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. BMO Capital Markets decreased their price target on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating for the company in a research note on Thursday, July 18th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Friday, August 9th. Ten investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $43.63.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $14.31 on Monday. The stock has a market cap of $739.87 million, a price-to-earnings ratio of -5.86 and a beta of 2.83. 4D Molecular Therapeutics has a fifty-two week low of $9.44 and a fifty-two week high of $36.25. The firm’s 50-day simple moving average is $19.82 and its 200 day simple moving average is $24.66.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 8th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.09. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $1.90 million. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.98 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.